• Follow the Money: Lymphatic System Platform, Endovascular Device System, Generative AI For Small Molecule Therapies, More

    Bio-IT World | Seaport Therapeutics plans to advance their Glyph platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms and has demonstrated clinical proof-of-concept; Nectero Medical will accelerate the execution of the Phase II/III (stAAAble) trial and to support the submission of a New Drug Application with the U.S. Food and Drug Administration for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST) System; DeepCure will further develop its generative AI and physics-based engine to innovate the discovery of small molecule therapies for challenging targets; more.

    Apr 24, 2024
  • AI Ushers in HPC Revival Says TACC’s Dan Stanzione

    Bio-IT World | High performance computing is enjoying an extreme vindication, said Dan Stanzione, Associate Vice President for Research at The University of Texas at Austin and Executive Director of TACC. In the opening plenary presentation at last week’s Bio-IT World Conference & Expo, Stanzione said that after years of cloud computing hype, artificial intelligence now demands traditional high performance computing architecture.

    Apr 23, 2024
  • Unlocking Targeted Cancer Care: Biomarkers as the Key to Personalized Treatments

    Bio-IT World | In modern medicine, biomarkers stand as pivotal indicators of biological processes or responses to therapeutic interventions, signaling a new era in clinical trial design and patient care. The driving idea behind the use of these tools is that by integrating the right biomarker information, scientists can properly select patients who are most likely to benefit from a particular therapy.

    Apr 19, 2024
  • New Products Win Praise at 2024 Bio-IT World Best of Show Awards

    Bio-IT World | Bio-IT World announced six Best of Show winners yesterday at the 2024 Bio-IT World Conference & Expo in Boston. Honored new products came from winning companies including Combinatics, Osprey, Maxis.IT, Nurocore, Velsera, and Xybion.

    Apr 16, 2024
  • Age of Opportunity: Artificial Intelligence and the Precision Medicine Future

    Bio-IT World | At the Precision Med TriConference 2024, Illumina Ventures partner Mara Aspinall sat with Eric Topol, endowed chair and executive VP and professor at Scripps Translational Science Institute, in a fireside chat to discuss precision medicine and artificial intelligence (AI). With three published books and more than 1,200 peer reviewed publications, Topol is one of the industry’s leading minds on digital medicine, and from his perspective, AI needs to be adapted sooner.

    Apr 16, 2024